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Model-informed drug dosingDevelopmental changes in children can affect the disposition and clinical effects of a drug, indicating that scaling
an adult dose simply downper linearweight can potentially lead to overdosing, especially in very young children.
Physiologically-based pharmacokinetic (PBPK) models are compartmental, mathematical models that can be
used to predict plasma drug concentrations in pediatric populations and acquire insight into the influence of
age-dependent physiological differences on drug disposition. Pediatric PBPK models have generated attention
in the last decade, because physiological parameters for model building are increasingly available and regulatory
guidelines demand pediatric studies during drug development. Due to efforts from academia, PBPKmodel devel-
opers, pharmaceutical companies and regulatory authorities, examples are now available where clinical studies
in children have been replaced or informed by PBPKmodels. However, the number of pediatric PBPKmodels and
their predictive performance still lags behind that of adult models. In this reviewwe discuss the general pediatric
PBPKmodel principles, indicate the challenges that can arise when developing models, and highlight new appli-
cations, to give an overview of the current status and future perspective of pediatric PBPK modeling.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Contents
1. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
2. Pediatric PBPK model development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
3. Use of models to mechanistically describe ADME processes . . . . . . . . . . . . . . . . . . . . . . . . . . 3
4. 4 Exploratory pediatric PBPK models. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
5. Physiologically-based toxicokinetic models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
6. Quality control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
7. Regulatory applications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
8. Future perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
9. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11interaction; GFR, glomerular fil-
lasma partitioning coefficient;
rter; OCT, organic cation trans-
, UDP-glucuronosyltransferase..
teplein 21, Room k0.10 (route
Russel).
nc. This is an open access article und1. Introduction
New drugs require pediatric studies as part of their market authori-
zation, while marketed drugs often lack information on pediatric effi-
cacy, safety and dosing (EMA, 2007; FDA, 2002/2003; Frattarelli, et al.,
2014; Sachs, Avant, Lee, Rodriguez, & Murphy, 2012). To find out what
doses are suitable for different age groups, it is important to realize
that many developmental processes are not reflected by simple scalarser the CC BY license (http://creativecommons.org/licenses/by/4.0/).
2 L.F.M. Verscheijden et al. / Pharmacology & Therapeutics 211 (2020) 107541like body weight or body surface area (Cella, Knibbe, Danhof, & Della
Pasqua, 2010). Drug metabolizing enzyme or transporter activity
show protein-specific and organ-dependent developmental profiles
(Daood, Tsai, Ahdab-Barmada, & Watchko, 2008; Lam et al., 2015;
Mooij et al., 2014; Sadler et al., 2016; Upreti & Wahlstrom, 2016; van
Groen et al., 2018). Moreover, other processes involved in the disposi-
tion of drugs also change in a nonlinear relationship with growth and
development, as was reviewed recently (van den Anker, Reed,
Allegaert, & Kearns, 2018).
Modeling and simulation has evolved as one of the cornerstones of
pediatric drug development by making optimal use of available data
(Manolis et al., 2011). In population PK (popPK) models, parameters
are computationally scaled/fitted in order to best describe in vivo mea-
sured drug concentrations. In this approach patient-specific characteris-
tics can be identified allowing for a more individualized therapy,
although a robust estimation of population PK parameters requires rel-
atively rich pharmacokinetic data, especially when multiple
characteristics/co-variates are studied. Moreover, a PopPK parameter
will reflect a combination of several physiological and drug-related pro-
cesses, which is difficult to extrapolate to other populations or drugs
(Brussee et al., 2018; Brussee et al., 2018). PBPK models provide mech-
anistic PK predictions and although the derivation of the required pa-
rameters could be challenging, theoretically they are more suitable for
between-population or between-drug PK predictions (W. Zhou et al.,
2018; W. Zhou et al., 2016). Integrating developmental changes in
PBPK models has proven to be successful in predicting doses across
the pediatric age span (Leong et al., 2012; Mansoor, Ahmad, Alam
Khan, Sharib, & Mahmood, 2019). More specifically, regulatory author-
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Fig. 1. “Learn, confirm and apply” development cycle used to build and optimize pediatric PBP
Qbo, Qhe, Qki, Qmu, Qsk, Qsp, Qgu, Qha, Qre, Qli denote blood flows towards, lung, brain, a
tissues, and from liver, respectively (e.g. Qlu = 300 L ∗ h−1 in adults). Physiological (system) p
in PBPK models.encourage their use in pediatric drug development (Leong et al.,
2012). The development of PBPK and/or PopPKmodels is in accordance
with FDA regulations (e.g. pediatric decision tree) as in any case pediat-
ric drug pharmacokinetic (PK) and safety data need to be evaluated in
order to bridge from the adult to the pediatric population.
1.1. PBPK modeling in adults and children
PBPKmodels represent the body as anatomically and physiologically
recognizable compartments in which the processes of drug absorption,
distribution,metabolism and excretion (ADME) are describedwith a set
of differential equations. PBPK models provide a mechanistic frame-
work that separately includes physiological parameters (often also re-
ferred to as system specific parameters), drug-related parameters, and
parameters reflecting trial design,which aims to cover the complex pro-
cesses governing drug disposition (Fig. 1). Models range from a simple
minimal setup, consisting of only a few essential compartments, to
full-body PBPK models in which all major organs in the body are repre-
sented by compartments connected through blood flow (Kuepfer et al.,
2016; Upton, Foster, & Abuhelwa, 2016). Much progress has beenmade
in accurately expressing the relevant physiological processes in terms of
accurate parameters. While PBPK models usually consist of many pa-
rameters and developing a model may be labor intensive, previous
models can be used to build upon as physiological parameters are not
expected to change within a population of interest, whichmarkedly re-
duces the effort that is needed for model building (Rostami-Hodjegan,
2012). Next to the physiological parameters, a variety of drug-related
data affecting pharmacokinetics need to be obtained, which largely


















































K models based on physiological, drug-related and trial design parameters. Qlu, Qbr, Qad,
dipose tissue, bone, heart, kidney, muscle, skin, spleen, gut, liver (arterial flow), rest of
arameters, drug-related parameters and trial-design parameters are separately included
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population-dependent system parameters. They have successfully
been translated from animals to humans (Ball, Bouzom, Scherrmann,
Walther, & Decleves, 2012; Bi, Deng, Murry, & An, 2016; Lukacova
et al., 2016; Parrott et al., 2011), from Caucasians to different ethnicities
(Feng et al., 2016;Matsumoto et al., 2018), and fromhealthy to diseased
populations (Radke et al., 2017; Rasool, Khalil, & Laer, 2015; Rhee,
Chung, Yi, Yu, & Chung, 2017). Similarly, extrapolations from adults to
children are based on adapting age-dependent adult physiological pa-
rameters to values appropriate for children. This approach is commonly
applied in thedevelopment of pediatricmodels to evaluate key pharma-
cokinetic processes and confirm age-unrelated drug-dependent param-
eters in an adult population, before introducing age-related pediatric
physiological parameters, for which data can be more sparse (Maharaj
& Edginton, 2014).
Pediatric PBPKmodeling has developed from ‘proof of principle’ to a
valuable tool for the prediction of pharmacokinetics in children
(Yellepeddi et al., 2018). Even more, PBPK-PD (PBPK-pharmacody-
namic) modeling is increasingly used to predict drug effects. The in-
creased interest is also reflected by an exponential rise in the number
of publications on this topic during the last decade. On the other hand,
the number of pediatric PBPK models and their predictive performance
still lags behind adultmodels (Grimstein et al., 2019; Jamei, 2016; Sager,
Yu, Ragueneau-Majlessi, & Isoherranen, 2015; Templeton, Jones, &
Musib, 2018). The aim of this review is to (1) discuss the use of pediatric
PBPK models for different purposes and identify challenges in model
building, (2) provide key considerations to evaluate pediatric PBPK
model quality, and (3) to give a future perspective on model develop-
ment that will further increase their quality and acceptance, as well as
their wider applicability into clinical care.
2. Pediatric PBPK model development
A tutorial for a general workflow to develop a pediatric PBPK model
was described by Maharaj et al. and will not be further discussed here
(Maharaj, Barrett, & Edginton, 2013;Maharaj & Edginton, 2014). Trends
between adult and pediatric physiological parameters are summarized
in Table 1.
In general, it is considered good practice to develop an adult model
first before a pediatric model is built, to obtain insight into key pharma-
cokinetic processes and allow for the verification of age-independent
drug-related parameters. Some of the physiological parameters that
are subsequently included in the pediatric model are well established,
such as organ volumes, however, information on others can be sparse
or absent (e.g. transporter expression). This indicates that dependent
on the route of administration (e.g. oral versus intravenous dosing)
and the drug involved (e.g. CYP3A4 substrate versusUGT substrate) con-
fidence in the model-predicted outcomes will be determined by the
(un)certainty of the estimates for the included parameters. Although
important information gaps may exist in ADME-related physiology for
specific drug models, a pediatric PBPK model can be judged ‘fit for pur-
pose’ if the relevant patterns related to age can be described and suffi-
ciently verified with clinical data.
For pediatric model development, it is valuable to obtain PBPK drug-
specific parameters from human in vitro studies that can be scaled to
in vivo parameters (in vitro-in vivo extrapolations (IVIVE), or also called
“bottom up approach”). For example, an in vitro clearance value can be
calculated from recombinant drugmetabolizing enzyme activity, which
is subsequently scaled to whole liver clearance by taking into account
age-appropriate liver weight and enzyme expression per gram. Such
an approach can contribute to the development of first in child dosing
regimens in case it is not possible to scale or fit parameters based on
comparison of predicted model output with measured drug concentra-
tions. In addition, it results in better mechanistic insight into the under-
lying ADME processes, for example the relative contribution of
individual drug metabolizing enzymes in clearance (Jaroch, Jaroch, &Bojko, 2018; Johnson et al., 2018; Scotcher, Jones, Posada, Rostami-
Hodjegan, & Galetin, 2016).
In practice, a combination of in vitro data and in vivo-derived drug
concentrations are often used for model parametrization. If physiologi-
cal or drug-related parameters for PBPK models are not available, they
need to be scaled or fitted based on clinically measured drug concentra-
tion data. This “middle out approach” allows the quantification of pro-
cesses affecting PK and to explore potential differences between
adults and children (Emoto, Johnson, McPhail, Vinks, & Fukuda, 2018;
Zane & Thakker, 2014). Similarly, pediatric models will also benefit
from adult in vivo pharmacokinetic data. For instance, adult clearance
values can be used to estimate pediatric clearances if differences in en-
zyme expression and activity of the elimination pathways involved are
taken into consideration.
3. Use of models to mechanistically describe ADME processes
3.1. Absorption
Oral dosing is the preferred route of drug administration in children.
Multi-compartment absorptionmodels are used to predict drug absorp-
tion from different gut segments, in which the complex interplay be-
tween different physiological processes and their effect on absorption
is incorporated. Age-related processes accounted for oral absorption in
PBPKmodels are gastric emptying time, small and large intestinal tran-
sit time and intestinal surface area,which are only part of the physiolog-
ical processes subject to developmental differences (Table 2). Recently,
a gastro-intestinal model was built by Johnson et al. based on a review
of the literature. They recognized knowledge gaps in the ontogeny of
fluid volume dynamics in the GI tract, intestinal bile flows, and CYP en-
zyme and transporter expression. Nevertheless, disposition of the rela-
tively high solubility and permeability drugs, paracetamol and
theophylline, were predicted with good precision. In addition, accurate
predictionswere alsomade for the low solubility drug ketoconazole and
carbamazepine. (Cristofoletti, Charoo, & Dressman, 2016; Johnson,
Bonner, Tucker, Turner, & Jamei, 2018; Kohlmann, Stillhart, Kuentz, &
Parrott, 2017) (Table 2).
Intestinal protein ontogeny data for CYP3A4 show a developmental
increase in activitywhen childrenmature, whereas expression of the ef-
flux transporter P-glycoprotein appears to be stable from fetal age until
adulthood (Table 1, Fig. 2) (Johnson, Tanner, Taylor, & Tucker, 2001;
Konieczna et al., 2011). Knowledge on intestinal abundance of other
drug metabolizing enzymes and transporters is still limited. In that
case PBPK models are useful in combination with measured clinical
drug concentrations to explore developmental differences in enzyme
and transporter expressions that have not yet been characterized at
the protein level.
Models describing other routes of absorption such as dermal, pulmo-
nary and ocular drug absorption were developed previously for adults,
rodents and rabbits, however, for children they are scarce (Le Merdy
et al., 2019; Poet et al., 2000; Salar-Behzadi et al., 2017; Valcke &
Krishnan, 2010). One study describedmulti-route (oral, dermal, pulmo-
nary) exposure to drinking water toxicants in neonates and children,
providing proof of principle also for other xenobiotics including drugs
(Valcke & Krishnan, 2010).
3.2. Distribution
Once in the systemic circulation, a drug will be distributed to organs
and tissues, which is usually described in PBPK models by the (pre-
dicted) tissue-plasma partitioning coefficient (Kp) (Table 3)(Poulin &
Theil, 2000; Rodgers, Leahy, & Rowland, 2005; Rodgers & Rowland,
2006). Age-appropriate calculations of the Kp value of a drug is depen-
dent on the fractional volumes of tissue water and lipid, as well as frac-
tion of the compoundwhich is unbound in plasma. In general, neonates
and young children will have a higher percentage of tissue water and
Table 1





Developmental pattern Age range reported Ref.
Absorption Small intestinal
lengtha




Increase Neonates-adolescents (Koppen et al., 2017; Mirjalili, Tarr, & Stringer, 2017)
Gastric pH Stable, subject to
alkalinization by milk
feeds
Neonates-adolescents (Avery, Randolph, & Weaver, 1966; Schmidt et al., 2015; Whetstine, Hulsey, Annibale, &
Pittard, 1995)
Small intestinal pH Stable Neonates-children (Barbero et al., 1952; Fallingborg et al., 1990)
Gastric emptying Stable Neonates-adults (Bonner et al., 2015)













Fetuses-adults (Fakhoury et al., 2005; Johnson et al., 2001)
- CYP3A4c Increase
Distribution Tissue composition Fetuses-children
2 years of age
(Butte, Hopkinson, Wong, Smith, & Ellis, 2000; Carberry, Colditz, & Lingwood, 2010;
Malina, 1969)- Proteind Stable
- Waterd Decrease
- Fatd Increase
Organ volumesa Increase Neonates-adults (Ogiu, Nakamura, Ijiri, Hiraiwa, & Ogiu, 1997)
Organ blood flow Neonates-adults (Chiron et al., 1992; Schoning & Hartig, 1996; Williams & Leggett, 1989)
- Braina First increase, later
decrease
- Other organsa Increase
Carrier proteins Neonates- children
3 years of age
(Johnson et al., 2006; Kanakoudi et al., 1995; Maharaj, Gonzalez, Cohen-Wolkowiez,
Hornik, & Edginton, 2018; Sethi et al., 2016)- Albumine Increase
- A1AGPe Increase
Hematocritf First decrease, later
increase




2 years of age
(Bhatt et al., 2019; Divakaran, Hines, & McCarver, 2014; Johnson et al., 2006; Salem et al.,
































Increase Neonates-adults (Barter et al., 2008)
Elimination Glomerular
filtration ratea




Neonates-adults (Cheung, van Groen, Spaans, et al., 2019)
- Pgpc Increase















Pgp, P-glycoprotein; BCRP, Breast cancer resistance protein; MRP, Multidrug resistance protein; OATP, Organic anion transporter protein; CYP, Cytochrome P450; A1AGP, Alpha-1-acid
glycoprotein; UGT, Uridine diphosphate-glucuronyltransferase; BSEP, Bile salt export pump; NTCP, Sodium-taurocholate cotransporting polypeptide; OCT, Organic cation transporter;
MATE, Multidrug and toxin extrusion; URAT, Urate transporter; GLUT, Glucose transporter; OAT, Organic anion transporter.
a Absolute length, volume, flow or rate.
b mRNA expression.
c Protein expression.
d Percentage of body weight.
e Concentration.
f Percentage of blood volume.
Table 2




Pediatric systems parameters included Software
used
Age range Drug Ref.
Parrott et al. No Gut size, intestinal transit time Gastroplus® Neonate, infant Oseltamivir (Parrott et al.,
2011)
Johnson et al. Yes GI tract size, CYP3A4 ontogeny Simcyp® Quetiapine (Johnson et al.,
2014)
Khalil et al. Yes Radius and length of intestinal segments, effective





11d–17.7y Sotalol (Khalil & Laer,
2014)
Willman et al. Yes Gastric emptying time, small and large intestinal transit
time, effective surface area intestinal sections
PK-Sim® 0.5–18y Rivaroxaban (Willmann et al.,
2014; Willmann
et al., 2018)








Villiger et al. Yes Intestinal length, intestinal surface area, small intestinal








Moj et al. Yes Not stated PK-Sim® 0–17y Vorinostat (Moj et al., 2017)
Kohlman et al. No Gut size and GI transit times Gastroplus® Newborns-adolescents Carbamazepine (Kohlmann et al.,
2017)
Samant et al. No Not stated Gastroplus® 0–22y Desipramine (Samant et al.,
2017)
Johnson et al. No Gastric emptying, gastric and intestinal pH, intestinal
length and diameter, intestinal transit time, salivary









Yes Not stated PK-Sim® 3 m-12y Ciprofloxacin (Balbas-Martinez
et al., 2019)
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compared to adults (Table 1), which is reflected in altered Kp values.
These age-related changes may consequently result for a specific drug
in a different predicted volume of distribution per kg body weight
(Samant, Lukacova, & Schmidt, 2017).
Drug disposition into organs can also be described by diffusion-
limited compartments. This mainly will be useful in cases where de-
layed drug penetration into organs is expected and/or transporter-
mediated transfer of compounds across cell membranes needs to be
accounted for. Data on maturation of drug transporters in the different
organs are, however, limited and lagging behind the knowledge on
the expression profiles of drug metabolizing enzymes (Table 1). Proof
of principle for this approach was given in a study where OCT1-
mediated liver uptake of morphine was included in a pediatric PBPKmodel, which could be verified by comparison of predicted and mea-
sured clearance values (Emoto et al., 2018). Because morphine is a
high extraction drug, clearance ismainly dependent onmorphine deliv-
ery to the hepatocytes, which is influenced by hepatic blood flow and
OCT1-mediated liver uptake, and to a lesser extent by UGT2B7 activity
(Emoto, Johnson, Neuhoff, et al., 2018). First, OCT1 genotypewas inves-
tigated as a source of variation in morphine liver uptake in adults and
children older than 6 years of age (Emoto et al., 2017). Subsequently,
ontogeny of OCT1 and an optimized relation between cardiac output
and age, which influences hepatic blood flow, were included into the
pediatric PBPK model to describe the clearance in neonates and young
infants (Emoto et al., 2017; Emoto, Johnson, Neuhoff, et al., 2018). In a
follow-up study, the ontogeny of UGT2B7 expression was also included
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Most efforts have been directed at incorporating age-dependent
changes in metabolic clearance into pediatric PBPK models (Fig. 2,
Table 4). Data from in vitro assays (i.e. recombinant enzymes, human
liver S9 fractions, human liver microsomes, or human hepatocytes)
have been used to estimate hepatic clearance in adult models, which
can also be applied to pediatric models by taking into account reported
differences in enzyme expression/activity. Investigations on the expres-
sion ontogeny of hepatic CYP enzymes have resulted in accurate predic-
tions for children down to an age of 1 month for drug metabolism
covered by the enzymes CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6
and CYP3A4 (Table 4) (W. Zhou et al., 2018). An in vitro study on the on-
togeny profiles of different CYP enzyme activities, showed that for drugs
handled by CYP1A2 and CYP3A4 these values resulted in an underesti-
mation of the in vivo clearance in the pediatric age range (Johnson,
Rostami-Hodjegan, & Tucker, 2006; Salem, Johnson, Abduljalil, Tucker,
& Rostami-Hodjegan, 2014; Upreti & Wahlstrom, 2016). By using clini-
cally determined clearance values of midazolam and sufentanil (both
CYP3A4), theophylline and caffeine (both CYP1A2), the ontogeny for
these enzymes was further refined (Salem et al., 2014). Subsequently,
this was verified with clearance values for alfentanil (CYP3A4) and
ropivacaine (CYP1A2) (Salem et al., 2014). A major drawback is that
in vivo clearance data were obtained in ill children, which potentially
has affected enzyme activity, but a good correlation between predicted
and measured clearance values was found (Salem et al., 2014; Upreti &
Wahlstrom, 2016). Although CYP enzyme developmental patterns are
relatively well described, in several situations prediction of clearance
was complicated by the absence of maturation profiles of metabolizing
enzymes. Studies have been published describingmodels incorporating
GST- and UGT-mediated clearance, in which only theoretical functions
(i.e. not based on observed data) were used to describe enzyme ontog-
eny, for instance based on other isoenzymes or fitting tomeasured drug
concentrations.While this indicates that prediction for these enzymes is
more difficult, these efforts aid in further establishing their ontogeny
profiles. (Diestelhorst et al., 2014; Jiang, Zhao, Barrett, Lesko, &
Schmidt, 2013).
In neonatal and preterm models, measured drug concentration are
less well predicted by PBPK models compared to older children and
adults (Khalil & Laer, 2014; Templeton et al., 2018; T'Jollyn,
Vermeulen, & Van Bocxlaer, 2018). Recently, developmental physiolog-
ical parameters in the preterm/neonatal population were re-evaluated
to provide a bettermechanistic basis for this age group and drug plasma
concentrations for six drugs were accurately described (Abduljalil, Pan,
Pansari, Jamei, & Johnson, 2019a, 2019b). Another aspect considered
specifically in neonates is that system-specific parameters can change
rapidly over a relatively short period of time. In PBPK models parame-
ters usually are fixed for a “virtual individual” during the time course
of the simulation. However, to account for time varying physiology in
neonates, in other words, to include growth and/or maturation in vir-
tual individuals, a model has been developed in which the values for
physiological parameters are re-defined during the time course of the
(prolonged) simulation (Abduljalil, Jamei, Rostami-Hodjegan, &Fig. 2. Developmental patterns in enzyme and transporter expression or activity in
intestine, liver, kidney and brain. Solid lines indicate ontogeny profiles for which age-
related equations are described. Dotted lines with point estimates indicate expression/
activity levels at specific age groups. Refs: Intestine (Johnson et al., 2001; Konieczna
et al., 2011), liver (enzymes) (Salem et al., 2014; Upreti & Wahlstrom, 2016), liver
(transporters) (Prasad et al., 2016), kidney (Cheung, van Groen, Spaans, et al., 2019),
brain (Lam et al., 2015). Pgp, P-glycoprotein; CYP, Cytochrome P450; OCT, Organic
cation transporter; OAT, Organic anion transporter.
Table 3










Age range Drug Ref.
Samant et al. No Lucacova Gastroplus® 0–15 years Desipramine (Samant et al., 2017)
Emoto et al. Liver Rodgers and Rowland Simcyp® 0–3 years Morphine (Emoto, Johnson,
Neuhoff, et al., 2018)
Verscheijden
et al.








Brain Rodgers and Rowland PK-Sim® 0 years - adult Lorazepam (Maharaj et al., 2013)
Lukacova
et al.
All tissues Not applicable Gastroplus® 11 days - 17 years
and adults
Ganciclovir, valganciclovir (Lukacova et al., 2016)
Table 4
PBPK models including prediction of metabolic elimination.





Yun et al. CYP1A2, CYP2B6, CYP2C9, CYP2C19,
CYPD6, CYP2E1, CYP3A4
PK-Sim® 1 week -
adult
Alfentanil, diclofenac, esomeprazole, itraconazole, lansoprazole, midazolam,
ondansetron, sufentanil, theophylline, tramadol
(Yun & Edginton,
2019)




Theophylline, desloratidine, montelukast, diclofenac, esomeprazole,
lansoprazole, tramadol, itraconazole, ondansetron, sufentanil
(W. Zhou et al.,
2018)
Salem et al. CYP1A2, CYP3A4 Simcyp® 1 day -
adult




CYP1A2, CYP2A6, CYP2B6, CYP2C8,
CYP2C9, CYP2C19, CYP2D6, CYP2E1,
CYP3A
Simcyp® 1 day -
adult
Caffeine, cotinine, nicotine, cyclophosphamide, methadone, phenytoin,
tolbutamide, omeprazole, pantoprazole, propafenone, sevofluorane,
sufentanil, midazolam, sildenafil, theophylline, S-warfarin, alfentanil,







CYP1A2, CYP2B6, CYP2C8, CYP2C9,
CYP2C18/19, CYP2D6, CYP2E1,
CYP3A4/5,
Simcyp® 1 day -
adult






CYP1A2, CYP2E1, CYP3A, SULT,
UGT1A1, UGT1A1, UGT1A6, UGT1A9,
UGT2B7
PK-Sim® 1 day -
adult
Paracetamol, alfentanil, morphine, theophylline, levofloxacin (Edginton,
Schmitt, &
Willmann, 2006)
Bhatt et al. UGT2B7 Simcyp® 1 day -
adult
Morphine, zidovudine (Bhatt et al.,
2019)
Jiang et al. CYP1A2, CYP2C9, CYP2C19, CYP2D6,
CYP2E1, CYP3A4, SULT, UGT1A1,
UGT1A9, UGT2B15
Simcyp® 1 day -
adult
Paracetamol (Jiang et al.,
2013)
7L.F.M. Verscheijden et al. / Pharmacology & Therapeutics 211 (2020) 107541Johnson, 2014). In this model, parameters involved in metabolic clear-
ance e.g. CYP3A4 and CYP2C9 expression and liver weight were in-
cluded, which resulted in better correlations between predicted and
measured data for sildenafil (Abduljalil et al., 2014).
Finally, in case the relevant ontogeny profiles in children are ro-
bustly described in PBPK models, more complex age-related variation
in drug metabolism may be detected. For example, a change in relative
enzyme contribution during growth, as has been described for paracet-
amol and sirolimus, or a change in relative contribution of eliminating
organs, as described for caffeine (Filler, 2007; Mooij et al., 2017; Pons
et al., 1988).
3.4. Excretion
Renal excretion of drugs depends on (1) freely filtered drug that is
determined by glomerular filtration rate and protein binding, (2) tubu-
lar secretion, and (3) tubular reabsorption. Equations describing ontog-
eny profiles for glomerular filtration rate (GFR) have been reported in
multiple studies and used to estimate the amount of drug that is freely
filtered (Duan et al., 2017; Johnson et al., 2006; Rhodin et al., 2009;
Schwartz et al., 1976). In recently described models, GFR is predicted
based on ontogeny functions derived from inulin and 51CR-EDTA mea-
surements, which gives more accurate results than using the creatinine
clearance (Johnson et al., 2006; Rhodin et al., 2009). Inclusion of tubular
secretion and absorption via transporter-mediated processes haslagged behind in pediatric applications, as data on human membrane
transporter ontogeny were, until recently, very scarce (Table 5,
Fig. 2) (Cheung et al., 2019). By measuring the in vivo renal clearance
of the P-glycoprotein substrate digoxin over a broad age range, the
contribution of tubular secretion in children was used as a surrogate
marker for the transporter's ontogeny profile (Willmann et al., 2014).
This was done by subtracting the age-related GFR-mediated clearance
from total digoxin clearance, which enabled simulation of
rivaroxaban plasma concentrations (another P-glycoprotein sub-
strate) over the pediatric age range. In this case the authors assumed
that P-glycoprotein transport is the rate-limiting factor in tubular
substrate secretion.
In case the transporter involved is unknown, or no transporter-
specific substrate data is available to estimate transporter-mediated ab-
sorption or secretion, the ratio of GFRpediatric/GFRadult has been used as a
surrogate for pediatric renal clearance. However, this assumes thatmat-
urational processes in transporters are paralleling the development of
GFR, which is often not the case (Cheung, van Groen, Spaans, et al.,
2019; Duan et al., 2017; Johnson et al., 2006; Rhodin et al., 2009). The
limitation of this assumption is also exemplified by a PBPK study in
which thismethodwas used to scale pediatric clearance for nine renally
cleared drugs. Although for most children acceptable predictions were
obtained, a trend towards an overestimation of renal clearance was
found for children b2 years of age, indicating that physiological pro-
cesses that affect renal clearance differ quantitatively between adults
8 L.F.M. Verscheijden et al. / Pharmacology & Therapeutics 211 (2020) 107541and young children (W. Zhou et al., 2016). This might be explained by
lower renal proximal tubular transporter expression of P-glycoprotein
(apical), organic anion transporter (OAT)1, OAT3 and organic cation
transporter (OCT)2 (basolateral) in neonates and young children
(Cheung, van Groen, Spaans, et al., 2019). The largest overprediction
of renal clearance was observed for vancomycin, which is transported
by OCT2 (Sokol, 1991; W. Zhou et al., 2016). If urinary excretion of a
drug is of minor influence on its total body clearance, ontogeny of
renal clearance is often ignored inmodeling (Walsh et al., 2016).Model-
ing the clearance of renally excreted drugs hence awaits inclusion of
kidney transporter ontogeny and a means to scale in vitro to in vivo
transport rates. A recent study indicates that this indeed leads to better
predictions (Cheung et al., 2019). To our knowledge pediatric models
including age-appropriate elimination via other routes such as bile, ex-
halation and sweat glands are not yet reported.
4. 4 Exploratory pediatric PBPK models
4.1. Predictions of (target) tissue concentrations
Most PBPK models are used to describe plasma concentration-time
profiles, but due to their compartmental structure, tissue concentrations
can be predicted aswell, which likely correlate better with the pharma-
cological/toxicological effects (Gerard et al., 2010; Hornik et al., 2017).
Especially concentrations in brain are of interest, as this organ is
protected by the blood-brain barrier equipped with multiple drug up-
take and efflux transporters. For lipophilic drugs, relatively simple
blood flow-limited models might be sufficient due to the rapid transfer
of the drug into the brain and predictions can be done by calculating
brain-plasma partitioning coefficients (Alqahtani & Kaddoumi, 2016;
Donovan, Abduljalil, Cryan, Boylan, & Griffin, 2018). These models are
not suitable for more polar drugs, where low BBB permeability restricts
brain access resulting in low exposure levels and a lag-time between
plasma and brain concentrations. One group started with a
permeability-limited rat model that was adjusted for adult humans.
This model was further refined to allow predictions on brain morphine
extracellular fluid concentrations in children between 3 and 13 years of
age (Ketharanathan et al., 2018; Yamamoto et al., 2017; Yamamoto
et al., 2018). In another study, an adult PBPK-CSF model was extrapo-
lated to children between 3 months and 15 years of age and verified
with multiple drug CSF concentrations (Verscheijden, Koenderink, de
Wildt, & Russel, 2019). Both groups did not specifically consider the in-
fluence of age on brain transporter expression, which is of main interest
for further studies, as accumulating evidence indicates that at least P-
glycoprotein activity appears age-related in the pediatric population
(Nicolas & de Lange, 2019). Tissue concentrations in other organs have
been described using simple Kp-based predictions, for example in
skin, bone and lung (Hornik et al., 2017; Ogungbenro, Aarons, Cresim,
& Epi, 2015; Thompson et al., 2019).
To date, models for the estimation of tissue concentrations have
been more exploratory in nature as compared to models for predicting
the course of the plasma drug concentration. This is due to limited ac-
cess to tissue drug concentrations for verification, knowledge about dis-
position between different parts of an organ, and on organ transporter
ontogeny. For a better applicability of thesemodels, more studies are re-
quired to obtain mechanistic information on the processes that govern
tissue exposure.
4.2. Prediction of fetal tissue concentrations
By linking fetal compartments to a maternal PBPK model, combined
maternal and fetal ADME processes can be described. Maternal
pregnancy-induced changes have been reported for volume of distribu-
tion, enzyme activity, blood flows, and plasma albumin and alpha-acid
glycoprotein concentrations (Abduljalil, Furness, Johnson, Rostami-
Hodjegan, & Soltani, 2012). For the fetal model, physiologicalparameters and their developmental pattern are needed to predict
drug exposure (Abduljalil, Jamei, & Johnson, 2019; Ke, Greupink, &
Abduljalil, 2018). Recently, more data has become available for ontog-
eny of physiological parameters in the fetus, for instance concerning de-
velopmental patterns in organ volumes (Abduljalil, Jamei, et al., 2019;
Abduljalil, Johnson, & Rostami-Hodjegan, 2018; Zhang et al., 2017).
Quantitative information on drug transfer from the maternal side to
the fetal compartments can be obtained from clearance studies in the
isolated perfused human placental cotyledon, or by measuring drug
transfer over a cell line monolayer (De Sousa Mendes et al., 2017;
Schalkwijk et al., 2018; Zhang et al., 2017; Zhang & Unadkat, 2017). Pla-
cental perfusion experiments are usually performed with normal term
placentas, which means that transporter and enzyme expression are
likely to be different at a lower gestational age, making extrapolation
to earlier stages of pregnancy difficult. Experimentswith cell linemono-
layers suffer from similar problems, as quantification of transporter ex-
pression is needed for the complete gestational age range to correct for
the differences in abundance between fetal placenta and the cell system
used for predictions (Ke et al., 2018). In addition, parameter optimiza-
tion and model verification are challenging as for obvious reasons fetal
drug exposure data at an early gestational age may be hard to acquire.
Model verification of fetal compartments with cord blood is an impor-
tant source of data, although samples are only available at birth and dif-
ferences in timing between the last dose and sampling introduces
variability in the concentrations measured. Also single measurements
do not give information on the underlying fetal concentration-time pro-
files (Schalkwijk et al., 2018).
4.3. Predictions for monoclonal antibodies
Therapeutic use of monoclonal antibodies (mAbs) and large protein
molecules has grown rapidly over the years. Although their body dispo-
sition is rather different from that of small molecule drugs, PBPKmodels
can also be valuable in predicting the pharmacokinetics of biologicals
(Gill, Gardner, Li, & Jamei, 2016).Models formAbs require incorporation
of different physiological processes, compared to small molecules, such
as lysosomal degradation, lymph flows, endogenous antibody concen-
trations, and FcRn receptor-mediated recycling, which also show age-
related variation (Edlund, Melin, Parra-Guillen, & Kloft, 2015; Jones,
Mayawala, & Poulin, 2013; Malik & Edginton, 2018). Data is not yet
available for all processes affecting pharmacokinetics of mAbs, which
underscores the need for studies unraveling these developmental phys-
iological parameters. Nevertheless, an attempt was made to scale an
adult PBPK model to a pediatric variant for the therapeutic monoclonal
IgG antibodies bevacizumab and palivizumab and although many pa-
rameters were uncertain, this approach can be used as a framework
for building a generic pediatric PBPK model that captures all complexi-
ties (Hardiansyah & Ng, 2018).
4.4. Determine effects of non-maturational factors
In addition to age-related variation in ADMEprocesses, PBPKmodels
are very well suited to explore and/or incorporate the effect of non-
maturational factors, such as disease, genetics and drug-drug interac-
tions (DDIs) on pharmacokinetics (Zakaria & Badhan, 2018). For exam-
ple, depending on the maturation profiles of the proteins involved in a
DDI, the magnitude of interaction may be different in various age
groups, which indicates that information on enzyme/transporter pro-
tein ontogeny, and their effects on the interaction needs to be described
(Salem, Johnson, Barter, Leeder, & Rostami-Hodjegan, 2013). Simula-
tions of DDIs are not yet common practice in pediatric populations, al-
though some papers have been published, mainly on CYP3A4 (A. Li,
Yeo, Welty, & Rong, 2018; Ogungbenro, Aarons, & Cresim, & Epi, C. P.
G., 2015; Olafuyi, Coleman, & Badhan, 2017). In these studies, no verifi-
cation was performed in children b 2y of age, in which developmental
differences in CYP3A4 expression are expected to have the largest
Table 5
PBPK models including prediction of renal elimination.
Study GFR ontogeny Tubular secretion/absorption ontogeny Software
used
Age range Drug Ref.
Balbas-Martinez Rhodin
ontogeny
p-Aminohippuric acid ontogeny PK-Sim® 3 m-12y Ciprofloxacin (Balbas-Martinez et al., 2019)
Lukacova et al. PEAR module
ontogeny
Optimized to measured data Adult
transporter expression levels




(Lukacova et al., 2016)
Zhou et al. Johnson
ontogeny
Same as GFR ontogeny Simcyp® Neonates- adults Nine renally
cleared drugs
(W. Zhou et al., 2016)
Walsh et al. NA NA Simcyp® 0–12 months and
adults
Actinomycin D (Walsh et al., 2016)
Parrott et al. 1/10th of adult 1/10th of adult Gastroplus® Neonates, young
infants, adults
Oseltamivir (Parrott et al., 2011)
Duan et al. Johnson
ontogeny
Same as GFR ontogeny Simcyp® 1 day – 17 years Linezolid,
emtricitabine
(Duan et al., 2017)
Willmann et al. Rhodin
ontogeny
Digoxin tubular secretion (P-glycoprotein)
ontogeny
PK-Sim® Neonates-adolescents Rivaroxaban (Willmann et al., 2014)
Cheung et al. Not stated Kidney developmental drug transporter
expression data
Not stated 0–7 years and adults Tazobactam (Cheung, van Groen, Burckart,
et al., 2019)
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effects have been incorporated in adult models for patients with im-
paired kidney (Yee et al., 2017; L. Zhou et al., 2019) and liver function
(Rhee et al., 2017), but inclusion in pediatric models is hampered by
the lack of quantitative data on the pathophysiological processes (G. F.
Li, Gu, Yu, Zhao, & Zheng, 2016; Rasool et al., 2015; Watt et al., 2018).
This is also seen in studies where the effects of a reduction in blood
flowwere investigated, which at this stage could not bemechanistically
included, because of pathophysiological differences in organ blood flow
in children compared to adults (Emoto, Johnson, McPhail, et al., 2018;
Rasool, Khalil, & Laer, 2016). Effects of genetic polymorphisms have
been studied in pediatric PBPK models, often associated with changes
in metabolizing enzyme activity (Ogungbenro & Aarons, 2015; Zakaria
& Badhan, 2018). Similarly, genetic variation in transporters and target
receptors can be incorporated (Hahn et al., 2018). If more physiological
data about specific patient groups becomes available, better individual-
ized PBPK model predictions can be made allowing subclassification
within age groups, thereby reducing unexplained inter-individual vari-
ability and paving the way for more individualized modeling.4.5. PBPK-PD models
Determination of PD differences between adults and children is of
major importance to allow pediatric bridging studies for drugs in devel-
opment. Introducing the relevant pharmacodynamic processes into pe-
diatric PBPK models will be the next step to determine fully age-
appropriated drug doses. The structure of many different PBPK models
developed so far is relatively uniform, however, pharmacodynamic
modules have their unique structure that is dependent on available
knowledge and the process that is being described. Most straightfor-
ward is to compare drug concentrations with target thresholds in case
of antibiotics, although in a more complex model bacterial count over
time could be described (Mohamed, Nielsen, Cars, & Friberg, 2012;
Thompson et al., 2019). There are relatively few examples of models
that have incorporated a more complex pharmacodynamic component
for adults and children (Kechagia, Kalantzi, & Dokoumetzidis, 2015;
Kuepfer et al., 2016; Moj et al., 2017; Smith, Hinderliter, Timchalk,
Bartels, & Poet, 2014). An important aspect for future model develop-
ment will be the inclusion of age-related drug effects instead of
connecting an adult pharmacodynamic model to a pediatric pharmaco-
kinetic component, for which more developmental ex vivo and clinical
research is clearly needed (Marshall & Kearns, 1999).5. Physiologically-based toxicokinetic models
The sameprinciples for building a PBPKmodel are also appliedwhen
assessing the kinetics of a toxic compound, referred to as
physiologically-based toxicokinetic (PBTK) models. In fact, the
physiologically-based kinetic modeling approach has been around in
toxicology longer than in the field of pharmacology (Pelekis, Gephart,
& Lerman, 2001). These type of models are usually developed for differ-
ent animal species and subsequently translated to humans to predict in-
ternal exposure as part of the risk assessment of a wider range of
chemicals, like pollutants (Emond, Ruiz, & Mumtaz, 2017; Tohon,
Valcke, & Haddad, 2019), metals (Fierens et al., 2016; Kirman, Suh,
Proctor, & Hays, 2017), pesticides (Lu, Holbrook, & Andres, 2010;
Oerlemans et al., 2019) and industrial products (Edginton & Ritter,
2009). Children have also been considered as a vulnerable group at
risk, as they may experience relatively higher exposures to chemicals
and/or bemore sensitive to harmful effects. For example, a higher expo-
sure to bisphenol A was predicted in children, because of their lower
elimination capacity compared to adults and the potentially higher
weight-normalized intake (Edginton & Ritter, 2009). A difficulty en-
countered while predicting developmental toxicity is that compared
to PBPK models, human and particularly pediatric PBTK models often
will carry more uncertainty about the dose internalized, and hence
higher variability in predictions (Lu et al., 2010).6. Quality control
The widespread adoption of PBPK modeling in pediatric drug devel-
opment and personalized dosing, largely depends on the quality of the
models and their validity to accurately predict exposure. The variety
in claims made by authors on reliability of the model predictions can
be explained by differences in quality and certainty of model parameter
estimates. Confidence in modeling results could be increased by
performing simulation with similar drugs/formulations (Johnson,
Zhou, & Bui, 2014), or the ability to predict drug-drug interactions
(Ogungbenro et al., 2015).
Assessing the quality of PBPKmodels is a complicated task due to the
wide variety of different purposes for model use, difference in (mecha-
nistic) complexity, the number of data that is available for building and
verification, and heterogeneity in quality measures (Sager et al., 2015).
For pediatric PBPK models this might be even more difficult as also de-
velopmental processes need to be incorporated and validated. Depend-
ing on the purpose of the PBPK model, its quality needs to be evaluated
accordingly. In case a model is designed to replace clinical studies in
children, confidence in model performance ideally should be high and
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eses (e.g. age-related differences in ontogeny), a lower level of confi-
dence in less essential parameters could be acceptable (EMA, 2016).
To have more insight into model quality, the following key aspects
need to be considered while evaluating PBPK models.
6.1. Mechanistic uncertainty
Uncertainty in themechanistic bases of themodel increases the pre-
diction error, while translating processes affecting absorption, distribu-
tion and elimination from adults to children. For example, the
contribution of different enzymes involved in drug metabolism can be
unknown, or disease-mediated changes on physiological processes are
not quantitatively described (Johnson, Cleary, et al., 2018). This means
that assumptions are required, of which the impact onmodel outcomes
needs to be evaluated by sensitivity analysis.
6.2. Scaling/fitting parameters
If (multiple) parameters are scaled, uncertainties in other parame-
ters could be masked or compensated in case they are not uniquely
identifiable. Apparently acceptable concentration-time profiles pro-
duced by a model for one drug or (pediatric) population, will in this
case not be reproducible for another drug or in another population
(Calvier et al., 2018). Ideally, external datasets are needed to confirm
the validity of the scaled parameter in a learning-confirming cycle. As
a minimum requirement, biological plausibility of the scaled parameter
could be evaluated.
6.3. Quality and quantity of in vivo data for verification
The number and quality of data for verification is variable, ranging
from sparse or opportunistic data to dense clinical trial data. Models
are generally accepted when they correlate to observed data even if
they are sparse, although the latter requires extra caution if for example
a measured concentration-time profile is not available for comparison
with simulated data (Sager et al., 2015).
6.4. Software package
Multiple software programs are used for modeling and some can be
considered better validated, as they have been tested and employed by
a large number of users. Currently available commercial software pro-
grams for pediatric PBPK modeling include Gastroplus, Simcyp and
PK-Sim. Gastroplus has historically focused on prediction of drug ab-
sorption, and Simcyp is often used for prediction of DDI's, although
areas of application have been extended. The open access software plat-
form PK-Sim is another option for which no coding skills are required.
Manually coded models are more prone to errors even after review,
butmay bemore flexible in order to answer specific research questions.
6.5. Transparency
To gain insight into parameter certainty, ideally an overview of the
model parameters (drug-related as well as physiological parameters)
is described along with the references from which they originated.
7. Regulatory applications
Because physiological and drug-specific parameters are included
separately, PBPK models are suited to predict drug concentrations in a
population, or for applications where extensive clinical pharmacoki-
netic information is not yet available. Currently, of all PBPK models
used in drug approval applications submitted to the FDA about 15%
serve a pediatric purpose, which is more than seen for other “special
populations” like elderly, or patients with impaired renal or hepaticfunction (Grimstein et al., 2019; Jamei, 2016). PBPK modeling in gen-
eral, and pediatric PBPKmodeling in particular, is a relatively new disci-
pline, but its application is increasing rapidly in the majority of
pharmaceutical companies. Examples are now available where clinical
studies have been replaced or informed by pediatric PBPK simulation ef-
forts (Shebley et al., 2018; Wagner et al., 2015). For example, models
have been used to (1) set a starting dose in a clinical trial with eribulin
in children and adolescents 6–18 years of age, (2) bridge from immedi-
ate release to extended release quetiapine formulations in children and
adolescents 10–17 years of age, and (3) inform deflazacort dose adjust-
ments needed when given together with drugs that may cause interac-
tions in children and adolescents 4–16 years of age (FDA, 2016; Johnson
et al., 2014; Shebley et al., 2018). Regulatory authorities have recog-
nized thepotential of PBPKmodeling and guidelineswere issuedmainly
focused onwhat information should be incorporated in the PBPKmodel
documentation by pharmaceutical industry, which might further stan-
dardize the process of model development in regulatory applications
(EMA, 2016; FDA, 2018).
8. Future perspectives
PBPK modeling in children aids in predicting the pediatric pharma-
cokinetics of drugs for which no or sparse data is available. Whereas
model performance is currently more challenging for neonatal popula-
tions, drugs metabolized by non-CYP enzymes, drug transporter sub-
strates, and drugs which are orally absorbed, PBPK models are
continuously improved and refined in a learn-and-confirm cycle by
the inclusion of more accurate model parameters.
One aspect that could further improve pediatric PBPK model devel-
opment is to fill the gap in availability and quality of systems data. For
this purpose, quantitative proteomics is an attractive technique to as-
sess ontogeny patterns for absolute expression of drugmetabolizing en-
zymes and transporters in different organs and the interplay with other
co-variates. This approach is especially suitable for pediatric popula-
tions where a low number or size of samples is usually available. As
multiple proteins can be quantified at the same time, correlation be-
tween protein expression can also be considered (Achour, Barber, &
Rostami-Hodjegan, 2014; Heikkinen, Lignet, Cutler, & Parrott, 2015).
The number of studies in children is limited, pediatric PBPK modeling
therefore will require pooling of data, resources and knowledge. This
also includes combining tissue material, plasma and body fluid samples
from different institutions and biobanks to cover the full age range of
pediatric development.
In addition to obtaining better defined physiological parameters,
there is a need for verification of models. Opportunistic sampling of
plasma and other body fluids or tissues would be a way to obtain mea-
surements for drugs already on the market, which were not thoroughly
investigated previously (Hahn et al., 2019; Salerno, Burckart, Huang, &
Gonzalez, 2019). Open access publishing and publication of raw data
will aid in making optimal use of already available clinical data. If it is
still not possible to obtain enough data, micro-dosing studies could pro-
vide a good alternative, as long as saturation of enzymes and trans-
porters is not expected at therapeutic doses. By administering a small
amount of a labeled drug (often 1/100 of usual dose) its pharmacokinet-
ics can be determined, without the risks associated with potential toxic
effects (Mooij et al., 2017; Roth-Cline & Nelson, 2015). From amodeling
perspective, good quality clinical data is extremely valuable for studying
the ontogeny of system parameters in case biological samples are hard
to obtain (e.g. blood brain barrier transporter expression).
Whereas in the coming years pediatric PBPK model improvement
will be focused on prediction in specific age groups and for children hav-
ing co-morbidities by better capturing the underlying (patho)physio-
logical parameters, an area of potential future benefit is the use of
PBPK modeling in personalized medicine. This will require even more
detailed information on demographic, genotypic, and phenotypic char-
acteristics. Development of a “virtual twin” in which patient-specific
11L.F.M. Verscheijden et al. / Pharmacology & Therapeutics 211 (2020) 107541features like, age, weight, height, gender, ethnicity, and genetics of drug
metabolizing enzymes/transporters are taken into account in PBPK
models, will contribute to better personalized dosing and predictions
within specific age groups. This will allow pediatric PBPK models to
find their way into clinical practice (Tucker, 2017).
9. Conclusion
The application of pediatric PBPK models have gained momentum
over the last years, partly because their development has been stimu-
lated by the increased interest of regulatory authorities in this “special
population” and the obligation of investigating pharmacological differ-
ences between children and adults. Different pediatric PBPK models
have been developed for a wide variety of purposes, including substitu-
tion of clinical studies. While uncertainty in some physiological param-
eters is higher and less data might be available for model verification in
children, pediatric PBPK models have become more robust and start to
approach the mechanistic basis seen in their adult counterparts. In the
coming years model quality and mechanistic basis will further improve
by inclusion of more (reliable) physiological data, which will provide a
sound basis for pediatric model acceptance (Burckart & van den
Anker, 2019). In this way, with concerted efforts of academia, PBPK
model developers, industry and regulators, the use of this approach
will further expand and be applied to optimize drug development in
the pediatric population. The role of modeling and simulation in drug
development will undoubtedly increase and particular effort should
be invested in the development of these models for children, to exploit
the enormous potential of this evolution also for the pediatric
population.
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